U.S. Food and Drug Administration expands approval of Yervoy® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy ® (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older.
Merck and Pfizer collaborate with Corning
- Details
- Category: Pfizer
Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging with the introduction of Corning Valor™ Glass. This revolutionary pharmaceutical glass packaging solution enhances the storage and delivery of today's drug formulations and provides more reliable access to medicines essential to public health.
Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development.
Merck Biopharma Innovation Cup 2017
- Details
- Category: Merck Group
Merck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology. The Biopharma Innovation Cup is designed to support the professional development of post-graduate students and to foster innovation from a promising new generation of academic talent.
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
- Details
- Category: Novartis
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1]. Data will be presented at a key medical congress in the second half of 2017.
FDA Advisory Committee votes in favor of Pfizer's MYLOTARG (gemtuzumab ozogamicin) for acute myeloid leukemia
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk:benefit profile for MYLOTARG (gemtuzumab ozogamicin) 3 mg/m2 on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
- Details
- Category: Novartis
Novartis announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) unanimously (10-0) recommended approval of CTL019 (tisagenlecleucel), an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).
More Pharma News ...
- Amgen and QB3@953 announce winners of The Amgen Golden Ticket
- Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
- BESPONSA® approved in the EU for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- Jardiance® (empagliflozin) analysis reinforces established safety profile
- Merck awards €1.25 million to research projects through its 2017 Grant for Fertility Innovation (GFI)
- Roche acquires mySugr to form a leading open platform for digital diabetes management
- 'More than Systemic Sclerosis: The Inside Story' - patients reveal the unseen impact of lung fibrosis